|
Jan 24
|
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
|
|
Jan 24
|
PRESS DIGEST- Wall Street Journal - Jan 24
|
|
Jan 23
|
Health Care Roundup: Market Talk
|
|
Jan 23
|
Inhibrx Soared 176% Over Two Months — Now, Sanofi Is Buying It
|
|
Jan 23
|
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
|
|
Jan 23
|
Stocks to Watch Tuesday: Verizon, Spirit Airlines, Netflix, Alibaba
|
|
Jan 23
|
Sanofi to buy Inhibrx in deal worth up to $2.2B
|
|
Jan 23
|
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion
|
|
Jan 23
|
France's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal
|
|
Jan 23
|
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
|
|
Jan 22
|
UPDATE 1-Fate of most remaining Zantac lawsuits weighed by Delaware judge
|
|
Jan 22
|
Fate of most remaining Zantac lawsuits weighed by Delaware judge
|
|
Jan 18
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jan 18
|
The Zacks Analyst Blog Highlights Adobe, IBM, Sanofi, Enbridge and Itau Unibanco
|
|
Jan 17
|
Top Stock Reports for Adobe, IBM & Sanofi
|
|
Jan 17
|
Sanofi: Information concerning the total number of voting rights and shares - December 2023
|
|
Jan 17
|
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
|
|
Jan 16
|
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
|
|
Jan 16
|
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn’t One.
|
|
Jan 12
|
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
|